



PTO/SB/21 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/580,098
Filing Date	May 19, 2006
First Named Inventor	Adam McCluskey
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	65617US(54086)

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	List of Citations (1 page)
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	Copies of 11 references
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	Return Receipt Postcard
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	EDWARDS ANGELL PALMER & DODGE LLP		
Signature			
Printed name	Peter C. Lauro		
Date	September 11, 2007	Reg. No.	32,360

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EM 053203036 US, on the date shown below in an envelope addressed to:
MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 11, 2007

Signature:

(Peter C. Lauro)



Application No. (if known): 10/580,098

Attorney Docket No.: 65617US(54086)

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EM 053203036 US in an envelope addressed to:

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on September 11, 2007
Date

Signature

Peter C. Lauro, Esq.

Typed or printed name of person signing Certificate

32,360
Registration Number, if applicable

(617) 517-5509
Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (11 References) (1 page)
Information Disclosure Statement (2 pages)
Copies of 11 references
Transmittal (1 page)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service as Express Mail, Label No. EM 053203036 US, on the date shown below in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: September 11, 2007 Signature

(Peter C. Lauro)

Docket No.: 65617US(54086)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Adam McCluskey, *et al.*

Application No.: 10/580,098

Confirmation No.: Not Yet
Assigned

Filed: May 19, 2006

Art Unit: N/A

For: **METHODS AND AGENTS FOR
INHIBITING DYNAMIN-DEPENDENT
ENDOCYTOSIS**

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants invite the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08. Applicants respectfully request that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Applicants submit herewith copies of the references listed on the attached PTO/SB/08 to the extent that such references are not U.S. patents and U.S. patent publications, in accordance with 37 C.F.R. §1.98(a)(2).

In accordance with 37 C.F.R. §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(a) exists. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an


admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Applicants submit that the Information Disclosure Statement is in compliance with 37 C.F.R. §1.98 and Applicants respectfully request the Examiner to consider and make of record the references listed on the attached PTO/SB/08.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 C.F.R. 1.97(b)(3)). Therefore, Applicants believe that no fees are required for consideration and entry of this Information Disclosure Statement. Nevertheless, Applicants hereby authorize the Director to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 65617US(54086).

Dated: September 11, 2007

Respectfully submitted,

By 

Peter C. Lauro, Esq.

Registration No.: 32,360


EDWARDS ANGELL PALMER & DODGE LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 517-5509

Attorneys/Agents For Applicants



Used in Lieu of PTO/SB/08A/B
(Based on PTO 04-07 version)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/580,098	
			Filing Date	May 19, 2006	
			First Named Inventor	Adam McCluskey	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	65617US(54086)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Wikipedia information on Curcumin: < http://en.wikipedia.org/wiki/Curcumin >	
	CB	Ohmichi, M., Pang, L., Ribon, V., Gazit, A., Levitzki, A. and Saltiel, A.R. (1993) The tyrosine kinase inhibitor tyrphostin blocks the cellular actions of nerve growth factor. <i>Biochemistry</i> 32 : 4650-4658.	
	CC	Gazit, A., Oshero, N., Posner, I., Yaish, P., Poradosu, E., Gilon, C. and Levitzki, A. (1991) Tyrophostins. Heterocyclic and α -substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. <i>J. Med. Chem.</i> 34 : 1896-1907.	
	CD	Mazumder, A., Gazit, A., Levitzki, A., Nicklaus, M., Yung, J., Kohlhagen, G. and Pommier, Y. (1995) Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type I integrase. <i>Biochemistry</i> 34 : 15111-15122.	
	CE	Gazit, A., App, H., McMahon, G., Chen, J., Levitzki, A. and Bohmer, F.D. (1996) Tyrphostins. 5. Potent inhibitor of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. <i>J. Med. Chem.</i> 39 : 2170-2177.	
	CF	Gazit, A., Oshero, N., Gilon, C. and Levitzki, A. (1996) Tyrphostins. 6. Dimeric benzylidenemalononitrile tyrphostins: potent inhibitors of EGF receptor tyrosine kinase <i>in vitro</i> . <i>J. Med. Chem.</i> 39 : 4905-4911.	
	CG	Levitzki, A., Gazit, A., Oshero, N., Posner, I. and Gilon, C. (1991) Inhibition of protein-tyrosine kinases by tyrphostins. <i>Methods in Enzymology</i> 201 : 347-361.	
	CH	Posner, I., Engel, M., Gazit, A. and Levitzki, A. (1993) Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. <i>Molecular Pharmacology</i> 45 : 673-683.	
	CI	Levitzki, A. and Gilon, C. (1991) Tyrphostins as molecular tools and potential antiproliferative drugs. <i>Trends in Pharmacological Sciences</i> 12 : 171-174.	
	CJ	Wijetunge, S. and Hughes, A.D. (1995) Effect of platelet-derived growth factor on voltage-operated calcium channels in rabbit isolated ear artery cells. <i>Br.J. Pharmacol.</i> 115 : 534-538 (ABSTRACT).	
	CK	Wijetunge, S., Lymn, J.S. and Hughes, A.D. (2000) Effects of protein tyrosine kinase inhibitors on voltage-operated calcium channel currents in vascular smooth muscle cells and pp60 ^{c-src} kinase activity. <i>British Journal of Pharmacology</i> 129 : 1347-1354.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------